Inicio / Hematología / Abstracts de hematología / Selective inhibitors of…

Selective inhibitors of nuclear export in aggressive B-cell lymphomas

0 / 5 (0 votos)
Selective inhibitors of nuclear export in aggressive B-cell lymphomas

The Lancet Haematology

Fecha de publicación: 01 July 2020

DOI: https://doi.org/10.1016/S2352-3026(20)30178-2

Autores: Annalisa Chiappella, Paolo Corradini

Background: The prognosis of relapsed or refractory diffuse large-B cell lymphoma (DLBCL) after first-line treatment is poor, particularly in patients not eligible to high-dose treatment or not benefiting from autologous transplantation. Anti-CD19 chimeric antigen receptor (CAR) T cells, axicabtagene ciloleucel and tisagenlecleucel, have been recently approved for the treatment of relapsed or refractory DLBCL after failure of at least two previous lines of systemic therapy, with promising results in terms of complete response (54–64%) and overall survival (59–64% at 12 months). There is currently no consensus on treatment for patients who are not eligible for CAR T-cell therapy, although several novel drugs are under investigation. 

Leer más

Comentarios

Para dejar un comentario antes debes iniciar sesión:

¿No tienes una cuenta?

Regístrate a través de éste enlace.